Holen Sie sich die Stockscreener-App
109.98
1.85%
-2.07
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead (GILD) Stock Dips in Trading, But 72% Yearly Gain Highlights Powerful Uptrend - Daily Chhattisgarh News
Transcript : Gilead Sciences, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 11 - marketscreener.com
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know - MSN
Gilead hit with FDA clinical hold for batch of HIV trials - Pharmaceutical Technology
Gilead Sciences Reports Promising CAR-T Therapy Results for Glioblastoma Treatment - geneonline.com
Gilead’s Trodelvy wins Korean coverage for breast cancer -- too late for some and still off-limits up front - koreabiomed.com
Levi & Korsinsky Investigates Possible Securities Fraud by Gilead Sciences, Inc. (GILD) - ACCESS Newswire
Gilead Sciences' Lenacapavir Provides 'Solid' Switching Opportunities for Current PrEP Users, RBC Says - marketscreener.com
Ex-Dividend Reminder: Gilead Sciences, CONMED and Thermo Fisher Scientific - Nasdaq
Gilead pauses trials of HIV combination therapy - statnews.com
Citi sees Gilead clinical holds as only ‘minor setback’ - Yahoo Finance
Gilead weekly oral hold should not affect lenacapavir PDUFA, says RBC Capital - Yahoo Finance
FDA placed clinical hold on Gilead HIV treatment trials of GS-1720 - Yahoo Finance
Gilead Sciences price target raised to $95 from $92 at RBC Capital - Investing.com
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down - Yahoo Finance
Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views? - Nasdaq
Pharmalittle: We’re reading about Trump and drug prices, Gilead trial delays, and more - statnews.com
Gilead Sciences (GILD) Sees Price Target Boost from RBC Capital | GILD Stock News - GuruFocus
Gilead (GILD) Faces Setback with FDA Hold on HIV Treatment Trials | GILD Stock News - GuruFocus
Gilead’s HIV combo trials halted by FDA amid safety concerns - The Pharma Letter
In Brief: Gilead HIV Trials On Hold Over Safety Signal - insights.citeline.com
Five things for pharma marketers to know: Wednesday, June 11, 2025 - Medical Marketing and Media
USFDA places clinical hold on Gilead Sciences trials testing HIV pill combination - Medical Dialogues
Why Gilead Scinces Stock Tumbled on Tuesday - The Globe and Mail
Why Gilead Scinces Stock Tumbled on Tuesday - The Motley Fool
FDA slaps holds on five of Gilead's HIV studies - FirstWord Pharma
Gilead Sciences (GILD) Stock Dips 1.59%, Pausing an Impressive Yearly Rally - Daily Chhattisgarh News
Gilead at Goldman Sachs Healthcare Conference: Strategic Growth Insights - Investing.com Australia
Gilead at Goldman Sachs Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com UK
US FDA pauses Gilead trials testing experimental HIV pill combination - Reuters
Gilead Sciences (GILD) Faces FDA Hold on HIV Drug Trials - GuruFocus
Gilead (GILD) Faces Setback with FDA Hold on Drug Trials | GILD Stock News - GuruFocus
US FDA places clinical hold on Gilead trials testing HIV pill combination - WSAU
Gilead’s HIV Combo on Hold, With No Impact on FDA’s Pending Lenacapavir Decision - BioSpace
Gilead Says FDA Puts Clinical Hold on HIV Combination Trials - marketscreener.com
Gilead faces clinical hold on trials of two HIV candidates - Seeking Alpha
Gilead (GILD) Faces Clinical Hold Due to Safety Concerns in HIV Trial | GILD Stock News - GuruFocus
FDA slaps clinical hold on multiple Gilead HIV combo therapy trials, shares fall - Fierce Biotech
Gilead (GILD) Shares Dip Amid FDA Hold on HIV Trials | GILD Stoc - GuruFocus
RBC Capital maintains Gilead Sciences stock rating, sees access hurdles - Investing.com
Gilead (GILD) Faces Clinical Hold on HIV Treatment Study | GILD Stock News - GuruFocus
GILD Faces Setback with FDA Clinical Hold on HIV Treatment Trials | GILD Stock News - GuruFocus
Gilead shares fall after FDA places clinical hold on HIV treatment trials - Proactive financial news
Gilead Sciences shares hit after HIV studies placed on hold by FDA - StreetInsider
US FDA places clinical hold on Gilead trials testing HIV pill combination By Reuters - Investing.com
FDA Pauses Trials of Gilead HIV Combination After Safety Signal - Bloomberg
US FDA places clinical hold on 2 Gilead trials of weekly HIV pill combination - Yahoo
US FDA Places Clinical Hold on Gilead Trials Testing HIV Pill Combination - US News Money
Gilead Sciences (GILD) Says FDA Placed Cilnical Hold On Hiv Treatment Trials - StreetInsider
Should You Be Impressed By Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE? - simplywall.st
'We are in a good spot': Gilead's new chief medical officer is committed to pipeline diversification - Fierce Biotech
2 Stocks, 100%+ Combined Gains - Investing.com
Gilead Reports Promising CAR-T Therapy Results for Glioblastoma Treatment - geneonline.com
Gilead Sciences Reports Promising Early Results for CAR-T Therapy in Treating Glioblastoma - geneonline.com
Gilead Sciences: Advancing New Ways To Help End the HIV - CSRwire
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):